European Commission Approves Gilteritinib for FLT3-Mutated, Relapsed/Refractory AML – ASH Clinical News
European Commission Approves Gilteritinib for FLT3-Mutated, Relapsed/Refractory AML – Acute Leukemias, Latest & Greatest – ASH Clinical News
Related Articles
Cognitive Dysfunction Can Lurk After Remission of Complement-Mediated Thrombotic Microangiopathy | ASH Clinical News | American Society of Hematology
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. In adults, complement clears excess neurotransmitters and old proteins from the brain and…
Call for ASH Clinical News Associate Editors (2025-2027) | ASH Clinical News | American Society of Hematology
The American Society of Hematology (ASH) is in search of an Associate Editor to join ASH Clinical News, the Society’s monthly news magazine for the…
You Make the Call: How would you treat venous sinus thrombosis in a patient with heterozygous prothrombin mutation and on testosterone replacement? | ASH Clinical News | American Society of Hematology
Ana Casanegra, MD, MS Associate Professor of Medicine Director, Thrombosis, Anticoagulation and Thrombophilia Clinic Mayo Clinic Rochester, MN Tanna Tan, MBBCh Resident, Internal Medicine Mayo…
Belamaf Plus Standard Care Shows Progression-Free Survival Benefit in R/R MM | ASH Clinical News | American Society of Hematology
Katie Robinson is a medical writer based in New York. Belantamab mafodotin (belamaf) treatment combined with standard-care therapies showed a progression-free survival (PFS) benefit in…
September 2024 | ASH Clinical News | American Society of Hematology
September 2024 | ASH Clinical News | American Society of Hematology September 2024 A Nickle Ain’t Worth a Dime Anymore NIH research funding doesn’t go…
Dose-Adjusted VEN-HMA Regimens Safe, Effective in Very Old Patients With AML | ASH Clinical News | American Society of Hematology
Leah Lawrence is a freelance health writer and editor based in Delaware. A significant portion of patients in their 80s and 90s with acute myeloid…
Isa-KRd Attains Deep, Durable Responses in MM Despite Missing Phase II Goal | ASH Clinical News | American Society of Hematology
Katie Robinson is a medical writer based in New York. In transplant-eligible patients with newly diagnosed multiple myeloma (NDMM), adding the CD38 monoclonal antibody isatuximab…
ASH Clinical News: September 2024 From the Desk Of…
ASH Clinical News Editor-in-Chief Aaron Gerds, MD, previews the upcoming September 2024 issue. Issue highlights include a feature article on the changes in f…
Call for ASH Clinical News Associate Editors (2025-2027) | ASH Clinical News | American Society of Hematology
The American Society of Hematology (ASH) is in search of an Associate Editor to join ASH Clinical News, the Society’s monthly news magazine for the…
Transfusions Linked With Mortality in General Population, Study Finds | ASH Clinical News | American Society of Hematology
Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. In a rare look at the effects of blood transfusions on long-term…